Janux Therapeutics, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue -0.21M3.64M8.61M8.08M10.59M
Gross Profit -0.21M3.64M8.61M8.08M10.59M
Operating items
Research & Development 3.04M26.24M53.44M54.92M68.39M
Selling, General & Administrative 1.80M10.33M22.26M26.14M41.05M
Operating Expenses 4.84M36.57M75.70M81.06M109.44M
Operating Income -4.84M-32.93M-67.09M-72.98M-98.85M
EBIT -4.84M-32.93M-67.09M-72.98M-98.85M
Non-operating items
Interest & Investment Income 0.26M4.03M14.69M29.85M
Non Operating Income -1.94M0.26M4.03M14.69M29.85M
Net income details
EBT -5.05M-32.67M-63.06M-58.29M-68.99M
Profit After Tax -6.78M-32.67M-63.06M-58.29M-68.99M
Income from Continuing Operations -5.05M-32.67M-63.06M-58.29M-68.99M
Consolidated Net Income -5.05M-32.67M-63.06M-58.29M-68.99M
Income towards Parent Company -5.05M-32.67M-63.06M-58.29M-68.99M
Net Income towards Common Stockholders -5.05M-32.67M-63.06M-58.29M-68.99M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 41.61M41.66M46.17M52.48M
Shares Outstanding (Diluted Average) 23.53M41.47M44.02M53.75M
EBITDA -6.78M-32.94M-64.32M-56.09M-67.50M
Shares Outstanding 1.05M41.24M41.62M46.25M59.06M